A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects.
Yoomin JeonNora LeeSeungjae BaekJaeDuk ChoiStanford JheeHoward LeePublished in: Drugs in R&D (2022)
ClinicalTrials.gov: NCT01037543 (23 December 2009).